{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:24:59Z","timestamp":1793942699453,"version":"4.8.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.035","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:03:19Z","timestamp":1792652599000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second Primary Malignancy in Patients With DLBCL Receiving CAR T Therapy and Other Systemic Anticancer Therapy: Real-World Evidence From a Large US National Claims Database"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omonefe O.","family":"Omofuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-2510","authenticated-orcid":false,"given":"Alexander","family":"Breskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hearnden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9736-0783","authenticated-orcid":false,"given":"Nandita","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-6364","authenticated-orcid":false,"given":"Christian","family":"Hampp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.035_bib0001","series-title":"Non-Hodgkin lymphoma","author":"Sapkota","year":"2023"},{"issue":"10091","key":"10.1016\/j.jtct.2026.10.035_bib0002","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2026.10.035_bib0003","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0004","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.035_bib0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jtct.2026.10.035_bib0007","unstructured":"National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: NHL \u2014 diffuse large B-cell lymphoma. Accessed June 24, 2026. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"issue":"11","key":"10.1016\/j.jtct.2026.10.035_bib0008","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2007.14.6068","article-title":"Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis","volume":"26","author":"Hemminki","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","article-title":"Second primary cancers among 109\u2009000 cases of non-Hodgkin's lymphoma","volume":"93","author":"Brennan","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.035_bib0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-023-05095-8","article-title":"Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors","volume":"102","author":"Zhan","year":"2023","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.10.035_bib0012","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00432-015-1979-1","article-title":"Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study","volume":"141","author":"Chien","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.035_bib0013","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1016\/S2352-3026(23)00212-0","article-title":"Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study","volume":"10","author":"Trab","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.035_bib0014","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2026.10.035_bib0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jtct.2026.10.035_bib0016","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.035_bib0017","unstructured":"U.S. Food and Drug Administration. 2024 safety and availability communications. Accessed June 24, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/2024-safety-and-availability-communications; 2024."},{"key":"10.1016\/j.jtct.2026.10.035_bib0018","unstructured":"U.S. Food and Drug Administration. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Accessed June 24, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed; 2024."},{"issue":"3","key":"10.1016\/j.jtct.2026.10.035_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.54","article-title":"Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: a multicenter cohort study","volume":"8","author":"Berning","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.035_bib0020","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.10.035_bib0021","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.035_bib0022","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","article-title":"Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy","volume":"8","author":"Melody","year":"2024","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.jtct.2026.10.035_bib0023","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.10.035_bib0024","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five year outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US lymphoma CAR-T cell consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.035_bib0025","unstructured":"Komodo Health Inc. Explore the healthcare map: the most complete view of the patient journey. Accessed June 24, 2026. https:\/\/www.komodohealth.com\/solutions\/healthcare-map\/."},{"key":"10.1016\/j.jtct.2026.10.035_bib0026","unstructured":"National Comprehensive Cancer Network. NCCN Recommendations (Version 3. 2025). Accessed June 24, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"suppl 5","key":"10.1016\/j.jtct.2026.10.035_bib0027","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2026.10.035_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107042","article-title":"Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin's lymphoma patients in England","volume":"127","author":"Miret","year":"2023","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.035_bib0029","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428194.2016.1228924","article-title":"Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy","volume":"58","author":"Danese","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.035_bib0030","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1002\/onco.13721","article-title":"Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.035_bib0031","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.035_bib0032","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2307\/2531492","article-title":"Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data","volume":"45","author":"Pepe","year":"1989","journal-title":"Biometrics"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.035_bib0033","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"20","key":"10.1016\/j.jtct.2026.10.035_bib0034","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.10.035_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1063986","article-title":"Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: case series and review of literature","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0036","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"33","key":"10.1016\/j.jtct.2026.10.035_bib0037","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0038","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-025-01676-4","article-title":"Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies","volume":"18","author":"Umyarova","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.10.035_bib0039","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.035_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.jtct.2026.10.035_bib0041","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.10.035_bib0042","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy side-effects: not all DNA damage is equal","volume":"14","author":"van den Boogaard","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.035_bib0043","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response: convergence of drugs and pathways","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0044","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.10.035_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.10.035_bib0046","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.jtct.2026.10.035_bib0047","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jtct.2026.10.035_bib0048","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2023012336","article-title":"Answering the \u201cDoctor, can CAR-T therapy cause cancer?\u201d question in clinic","volume":"8","author":"Banerjee","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.10.035_bib0049","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2026.10.035_bib0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.10.035_bib0051","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600847X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600847X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:42:58Z","timestamp":1793940178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600847X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S266663672600847X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.035","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Primary Malignancy in Patients With DLBCL Receiving CAR T Therapy and Other Systemic Anticancer Therapy: Real-World Evidence From a Large US National Claims Database","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}